Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Data from the BIOBADASER 3.0 Registry
04/09/2024
Adrián Quevedo-Rodríguez* 1 Lucía Otero-Varela 2 Fernando Sánchez-Alonso 2 Yanira Perez-Vera 1 Francisco Javier Manero Ruiz 3 Cristina Campos Fernández 4 Sara Manrique-Arija 5 Paloma Vela-Casasempere 6 Antonio Jose Mera-Varela 7 Cesar Diaz-Torne 8 Atusa Movasat 9 Blanca Garcia-Magallon 10 Inmaculada Ros 11 Carolina Perez-Garcia 12 Isabel Castrejon 13
EULAR 2024
DOI: 10.1136/annrheumdis-2024-eular.1760
https://ard.bmj.com/content/83/Suppl_1/785.1